Company profile: Precigen
1.1 - Company Overview
Company description
- Provider of bio-therapeutic control systems and platforms to minimize toxicity, including UltraCAR-T, a non-viral multigenic CAR-T cell therapy enabling rapid manufacturing with enhanced in vivo persistence and tumor response; ActoBiotics, microbe-based agents delivering disease-modifying treatments locally; and Exemplar Genetics gene-edited minipig models and preclinical services.
Products and services
- ActoBiotics: Develops a microbe-based platform to deliver disease-modifying therapeutics locally at disease sites, such as the intestine and mouth, for various disorders
- Exemplar Genetics: Delivers gene-edited minipig models and preclinical services to improve the translational value of research in human disease mechanisms and therapeutic development
- UltraCAR-T: Engineers a CAR-T cell therapy platform using non-viral multigenic delivery for rapid manufacturing and improved patient access, targeting cancer with enhanced in vivo persistence and tumor response
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Precigen
Trevi Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for uremic pruritus and chronic cough, including Haduvio—an investigational oral nalbuphine ER therapy targeting the central and peripheral nervous systems for idiopathic pulmonary fibrosis (IPF)-related cough and refractory chronic cough (RCC).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trevi Therapeutics company profile →
Imbria
HQ: United States
Website
- Description: Provider of clinical-stage cardiometabolic therapies centered on ninerafaxstat, an investigational cardiac mitotrope designed to enhance cellular energy metabolism by increasing energy per molecule of oxygen consumed. Conducts Phase 2 trials: IMPROVE-HCM (non-obstructive HCM), IMPROVE-ISCHEMIA (stable angina/chronic coronary syndrome), and IMPROVE-DiCE (type 2 diabetes with HFpEF).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Imbria company profile →
Pfizer
HQ: United States
Website
- Description: Provider of biopharmaceutical medicines and health care services, delivering affordable access to safe, effective treatments, including vaccines for infectious diseases (COVID-19, pneumonia, meningitis), oncology therapies, cardiovascular medicines for hypertension and cholesterol, anti-infectives (antibiotics, antivirals), treatments for inflammation and immunology, and therapies for rare genetic disorders addressing unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pfizer company profile →
Oxford Biomedica
HQ: United Kingdom
Website
- Description: Provider of gene and cell therapy solutions, offering lentiviral LentiVector and AAV platforms for development and manufacturing of gene therapies, plus CDMO services for viral vectors including tech transferred-in execution of client-defined methods, process development, GMP manufacturing, and regulatory support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oxford Biomedica company profile →
BioXcel Therapeutics
HQ: United States
Website
- Description: Provider of AI-driven drug re-innovation and therapeutics, including IGALMI, an FDA-approved sublingual film for acute agitation in adults with schizophrenia or bipolar I/II; BXCL501, an investigational dissolving dexmedetomidine film for agitation related to Alzheimer’s dementia and bipolar or schizophrenia; BXCL701, an oral innate immune activator under investigation for aggressive prostate, pancreatic, and other solid and liquid tumors; plus an Expanded Access Program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioXcel Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Precigen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Precigen
2.2 - Growth funds investing in similar companies to Precigen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Precigen
4.2 - Public trading comparable groups for Precigen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →